Regeneron Buys 23andMe in Bankruptcy Auction

Andrew Kessel

Mon, May 19, 2025, 11:42 AM 1 min read

• Regeneron Pharmaceuticals agreed to purchase 23andMe for $256 million in a bankruptcy court auction, the company said Monday.

• The move allows 23andMe to continue to provide DNA testing services.

• Regeneron pledged to “prioritize the privacy, security and ethical use of 23andMe’s customer data."

Regeneron Pharmaceuticals (REGN) agreed to buy DNA testing company 23andMe for $256 million in a bankruptcy court auction, the company said Monday.

The transaction will allow 23andMe, which filed for Chapter 11 bankruptcy in March, to continue providing consumer genome services uninterrupted.

Regeneron pledged to “prioritize the privacy, security and ethical use of 23andMe’s customer data” and said it will work with a court-appointed official to review its security practices. The deal is expected to close in the third quarter, pending bankruptcy court and regulatory approvals.

For Regeneron, the move is meant to aid its genetic research. “We believe we can help 23andMe deliver and build upon its mission… while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall,” Chief Science Officer George Yancopoulos said.

Shares of Regeneron edged 0.4% lower in recent trading and are down about 17% for 2025.

Read the original article on Investopedia